Skip to main content
Anna Halpern, MD, Oncology, Seattle, WA

Anna B Halpern MD

Hematologic Oncology


Physician

Join to View Full Profile
  • 825 Eastlake Ave ESeattle, WA 98109

  • Phone+1 206-288-1000

  • Fax+1 206-606-1025

Dr. Halpern is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2013 - 2016
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2009 - 2012
  • The Warren Alpert Medical School of Brown University
    The Warren Alpert Medical School of Brown UniversityClass of 2009

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2013 - 2026
  • IL State Medical License
    IL State Medical License 2009 - 2014
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, Mitoxantrone, and G-CSF with Dose-Escalated Mitoxantrone for relapsed/refractory Acute Myeloid Leukemia or Other H...  
    Kelda M Gardner, Vivian G Oehler, Heather A Smith, Anna B Halpern, Paul C Hendrie, Sarah A Buckley, Roland B Walter, Pamela S Becker, Ryan D Cassaday, Asma Anwar, Bart..., Haematologica

Abstracts/Posters

  • Treatment of Refractory Acute Myeloid Leukemia and High-Grade Myelodysplastic Syndrome: Implications of Further Care at an Academic Center Versus Community Setting
    Anna B. Halpern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ...
    Anna B. Halpern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myel...
    Anna B. Halpern, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Othe... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) Is Active and Well-Tolerated in Adults with Newly-Diagnosed Acute Lympho... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Sorafenib plus GCLAM Held Safe in AML, MDS Phase-1 Study
    Sorafenib plus GCLAM Held Safe in AML, MDS Phase-1 StudyApril 22nd, 2019
  • iHealthHome Supports Cancer Researchers on Home Telemonitoring Study of Leukemia Patients
    iHealthHome Supports Cancer Researchers on Home Telemonitoring Study of Leukemia PatientsDecember 1st, 2017

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: